| Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (NCT04446351) | GlaxoSmithKline | 2020-06-25 |
| Continued Treatment for Participants Enrolled in Studies of BXQ-350 (NCT04404569) | Bexion Pharmaceuticals, Inc. | 2020-06-08 |
| Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma (NCT03961841) | Sixth Affiliated Hospital, Sun Yat-sen University | 2020-06-01 |
| AIMS Cancer Outcomes Study (NCT04495790) | Advanced Integrative Medical Science Institute | 2020-05-18 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma (NCT04309084) | Celularity Incorporated | 2020-05-12 |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC (NCT04371796) | Sichuan Cancer Hospital and Research Institute | 2020-05-10 |
| ASCO Survey on COVID-19 in Oncology (ASCO) Registry (NCT04659135) | American Society of Clinical Oncology | 2020-04-19 |
| The Effects of a 6-week Balance, Agility, Strengthening Exercise Class (NCT04318574) | University of Manitoba | 2020-04-06 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML (NCT04310592) | Celularity Incorporated | 2020-03-12 |
| Effects of a Lay-led Anxiety and Depression Self-management Program for Cancer Patients (NCT04537195) | University of Aarhus | 2020-03-06 |
| Identifying Novel Variants in the DPYD Gene in Patients of Non-Western Descent (NCT04300361) | Leiden University Medical Center | 2020-03-01 |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) (NCT04249947) | Poseida Therapeutics, Inc. | 2020-02-28 |
| Sexual & Gender Minority Competency in Oncology (NCT04198090) | University of Rochester | 2020-02-17 |
| Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose. (NCT04288518) | Tomsk National Research Medical Center of the Russian Academy of Sciences | 2020-02-15 |
| Study to Evaluate the Usability of PointCheck (NCT04448314) | Leuko Labs, Inc. | 2020-02-11 |
| M7824 Related Adverse Effects in Adults With Cancer (NCT04267861) | National Cancer Institute (NCI) | 2020-01-28 |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (NCT05999994) | Eli Lilly and Company | 2020-01-22 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor (NCT04192344) | Abbisko Therapeutics Co, Ltd | 2020-01-20 |
| Improving the Safety of Fluoropyrimidine-based Chemotherapy (NCT04194957) | The Netherlands Cancer Institute | 2020-01-15 |
| LITT Followed by Hypofractionated RT for Recurrent Gliomas (NCT04181684) | University of Maryland, Baltimore | 2020-01-08 |
| Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (NCT03967223) | USWM CT, LLC | 2019-12-31 |
| Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (NCT06703346) | USWM CT, LLC | 2019-12-31 |
| Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (NCT05993299) | USWM, LLC (dba US WorldMeds) | 2019-12-31 |
| A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (NCT04147247) | Boehringer Ingelheim | 2019-12-23 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors (NCT04157517) | Teva Branded Pharmaceutical Products R&D LLC | 2019-12-12 |
| Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017 (NCT04144842) | Alligator Bioscience AB | 2019-12-03 |
| SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases (NCT03694015) | British Columbia Cancer Agency | 2019-12-02 |
| Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients (NCT04080843) | Zhejiang University | 2019-11-15 |
| Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC (NCT04133337) | Sichuan Cancer Hospital and Research Institute | 2019-11-01 |
| Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors (NCT04146610) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2019-11-01 |
| Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania (NCT04085510) | Wendie Berg | 2019-10-23 |
| A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (NCT03561259) | Jubilant DraxImage Inc. | 2019-10-21 |
| Integrative and Complementary Health Practices (PICS) (NCT04152109) | Universidade Federal do Triangulo Mineiro | 2019-10-02 |
| Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease (NCT04039100) | Rigshospitalet, Denmark | 2019-10-01 |
| Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer (NCT02964507) | GlaxoSmithKline | 2019-09-26 |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (NCT03911388) | M.D. Anderson Cancer Center | 2019-09-12 |
| THrombo-Embolic Event in Onco-hematology (NCT03826043) | Centre Antoine Lacassagne | 2019-09-09 |
| Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer. (NCT04061967) | Karolinska Institutet | 2019-08-19 |
| First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation (NCT04006301) | Janssen Research & Development, LLC | 2019-07-26 |
| [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake (NCT03872778) | Advanced Accelerator Applications | 2019-07-24 |
| A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (NCT03981796) | Tesaro, Inc. | 2019-07-18 |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (NCT04008797) | Eisai Inc. | 2019-07-11 |
| A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems (NCT03814005) | Takeda | 2019-07-10 |
| Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Information Provision, Patient Empowerment, Medication Compliance, Guideline Adherence and Quality of Life (NCT04595955) | Radboud University Medical Center | 2019-07-01 |
| PREMO Study: to Investigate Port REMoval Outcomes (NCT03948958) | Universitaire Ziekenhuizen KU Leuven | 2019-06-28 |
| A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) (NCT03948763) | Merck Sharp & Dohme LLC | 2019-06-26 |
| A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (NCT03964233) | Boehringer Ingelheim | 2019-06-20 |
| A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) (NCT03918278) | Merck Sharp & Dohme LLC | 2019-06-19 |
| A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (NCT03972150) | Boehringer Ingelheim | 2019-06-12 |
| Peer Support Program in Cancer Patients Elkar Laguntza (NCT05077371) | Joana Perez Tejada | 2019-06-01 |
| PATIENT VOICES Integration of Systematic Assessment of Patient Reported Outcomes Within Clinical Oncology Practice (NCT03968718) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2019-05-27 |
| Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study (NCT03895502) | Takeshi Morimoto | 2019-05-27 |
| Expressive Helping for Chinese-Speaking Cancer Patients and Survivors (NCT03945734) | New York University | 2019-05-20 |
| A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma (NCT04008082) | Eisai Co., Ltd. | 2019-05-14 |
| A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors (NCT03926013) | Janssen Research & Development, LLC | 2019-05-01 |
| Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives (NCT03954366) | pharmaand GmbH | 2019-04-25 |
| A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors (NCT03967093) | Bexion Pharmaceuticals, Inc. | 2019-04-15 |
| The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer (NCT03889626) | Fudan University | 2019-03-22 |
| Monitoring and Telecoaching of Physical Activity in Patients With Stage III and IV Non-small Cell Lung Cancer (NCT03883243) | KU Leuven | 2019-03-15 |
| A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (NCT03843359) | GlaxoSmithKline | 2019-03-12 |
| Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions (NCT03549273) | Catalysis SL | 2019-03-11 |
| A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers (NCT03783403) | Celgene | 2019-03-01 |
| Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling (NCT03760952) | Immatics US, Inc. | 2019-02-26 |
| Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a (NCT03697824) | GlaxoSmithKline | 2019-02-25 |
| Cognitive and Behavioral Intervention for the Management of Episodic Breathlessness in Patients With Advanced Disease (NCT04630743) | University of Cologne | 2019-02-09 |
| The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study (NCT04075305) | UMC Utrecht | 2019-02-01 |
| Resection of the Inferior Vena Cava Due to Tumor Involvement (NCT04154761) | Hospital Universitario Infanta Cristina | 2019-01-31 |
| Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (NCT03792724) | Clinica Universidad de Navarra, Universidad de Navarra | 2019-01-30 |
| Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015 (NCT03782467) | Alligator Bioscience AB | 2019-01-30 |
| Chemotherapy and Liver Cirrhosis in Frequently-associated Cancers (NCT04179773) | University Hospital, Lille | 2019-01-24 |
| Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) (NCT03739710) | GlaxoSmithKline | 2019-01-24 |
| Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 (NCT05553808) | GlaxoSmithKline | 2019-01-24 |
| Ivabradine to Prevent Anthracycline-induced Cardiotoxicity (NCT03650205) | University of Sao Paulo | 2019-01-22 |
| The Effectiveness of Nurse Navigators in Cancer Care (NCT05537870) | Taipei Medical University | 2019-01-17 |
| Rogaratinib (BAY1163877) in Chinese Patients (NCT03788603) | Bayer | 2019-01-07 |
| Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation (NCT03803436) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2019-01-02 |
| Cancer Survival in Reunion Island , 1998-2008 (SUCRE) (NCT02900287) | Centre Hospitalier Universitaire de la Réunion | 2019-01-01 |
| Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab (NCT03709706) | GlaxoSmithKline | 2018-12-31 |
| Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC (NCT03389256) | Sichuan Cancer Hospital and Research Institute | 2018-12-30 |
| Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry (NCT03712488) | Assiut University | 2018-12-15 |
| A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors (NCT03797391) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2018-12-13 |
| Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients (NCT03757182) | Cedars-Sinai Medical Center | 2018-12-05 |
| Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients (NCT03037840) | Southern Medical University, China | 2018-12-01 |
| Measuring the Electrical Properties of Malignant Tissues In Vivo (NCT02747225) | Southern Medical University, China | 2018-12-01 |
| Multi-modality Imaging in Peritoneal Carcinomatosis of Colorectal Origin (NCT03699332) | Radboud University Medical Center | 2018-12-01 |
| Measuring the Electrical Properties of Malignant Tissues Ex Vivo (NCT02747212) | Southern Medical University, China | 2018-12-01 |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676) | Juno Therapeutics, a Subsidiary of Celgene | 2018-11-29 |
| GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (NCT03693612) | GlaxoSmithKline | 2018-11-26 |
| 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors (NCT03366116) | National Cancer Institute (NCI) | 2018-11-05 |
| Parenteral Nutrition Therapy in Patients With Incurable Cancer (NCT04456647) | Norwegian University of Science and Technology | 2018-11-01 |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (NCT03602157) | UNC Lineberger Comprehensive Cancer Center | 2018-10-29 |
| First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) (NCT03666988) | GlaxoSmithKline | 2018-10-22 |
| Quantitative MR Imaging in Locally Advanced Cervical Cancer (NCT03210428) | Aarhus University Hospital | 2018-10-18 |
| Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (NCT03614728) | GlaxoSmithKline | 2018-10-16 |
| A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System (NCT03648372) | Takeda | 2018-10-01 |
| Promoting Physical Activity in Young Adult Cancer Survivors Using mHealth and Adaptive Tailored Feedback Strategies (NCT03569605) | UNC Lineberger Comprehensive Cancer Center | 2018-08-23 |
| A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide (NCT03495921) | Gradalis, Inc. | 2018-08-21 |
| Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients (NCT03626896) | NaviFUS Corporation | 2018-08-17 |
| Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001) (NCT03515824) | Merck Sharp & Dohme LLC | 2018-08-13 |